Skip to main content
. 2021 Jun 16;8:668808. doi: 10.3389/fmed.2021.668808

Table 2.

Meta-analysis showing the pooled adjusted risk of unfavorable COVID-19 outcomes in subjects with asthma or COPD.

Study details Meta-analysis Heterogeneity Publication bias GRADE rating
Lung disease Number of studies Number of participants Odds ratio (95% CI) p-value I2 Egger bias and p-value
Hospitalisation
Asthma 7 1,087,689 0.873 (0.726–1.049) 0.148 85.355 0.747p = 0.678 Moderate (downgraded due to high heterogeneity)
COPD 6 588,025 1.390 (1.307–1.478) <0.001 4.236 1.453p = 0.050 Moderate (downgraded due to possible publication bias)
ICU admission
Asthma 4 167,849 0.746 (0.545–1.020) 0.067 87.198 −1.979p = 0.653 Moderate (downgraded due to high heterogeneity)
COPD 9 197,108 1.336 (1.139–1.566) <0.001 66.643 1.537p = 0.075 Moderate (downgraded due to high heterogeneity)
Mortality (aORs)
Asthma 7 876,759 0.827 (0.711–0.961) 0.013 61.481 0.007p = 0.996 Moderate (downgraded due to high heterogeneity)
COPD 17 950,502 1.276 (1.176–1.385) <0.001 34.508 0.881p = 0.038 Moderate (downgraded due to possible publication bias)
Mortality (aHRs from Cox regression models)
Asthma 4 (5 outcomes) 122,786 0.930 (0.865–1.000) 0.049 64.176 1.400p = 0.414 Moderate (downgraded due to high heterogeneity)
COPD 8 (9 outcomes) 123,886 1.296 (1.170–1.436) <0.001 88.386 2.179p = 0.093 Moderate (downgraded due to high heterogeneity)

GRADE, Grading of Recommendations, Assessment, Development, and Evaluations; COPD, Chronic Obstructive Pulmonary Disease; aOR, adjusted odds ratio; aHR, adjusted hazard ratio.